Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
World game at war: why some European nations have threatened a World Cup boycott 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
Capital One Says AML Review Led to Closure of Trump Organization Accounts 
BEVERLY, Mass. and TORONTO, April 18, 2018 -- Hamilton Thorne Ltd. (TSX-V:HTL), a leading world-wide provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies (ART) and developmental biology research markets, today announced that it will release its financial results for the three months and year ended December 31, 2017 before market open on Wednesday, April 25, 2018. The press release, with accompanying financial information, will be posted on the Company’s website at www.hamiltonthorne.com and on www.sedar.com.
The Company will follow with a conference call on the same day, at 11:00 a.m. EDT to review highlights of results. All interested parties are welcome to join the conference call by dialing toll free 1-855-223-7309 in North America, or 647-788-4929 from other locations, and requesting Conference ID 3284638. A recording of the call will be available on Hamilton Thorne’s website shortly after the call.
About Hamilton Thorne Ltd. (www.hamiltonthorne.com)
Hamilton Thorne is a leading global provider of precision instruments, consumables, software and services that reduce cost, increase productivity, improve results and enable breakthroughs in Assisted Reproductive Technologies (ART) and developmental biology research markets. Hamilton Thorne markets its products and services under the Hamilton Thorne, Gynemed and Embryotech Laboratories brands, through its growing sales force and distributors worldwide. Hamilton Thorne’s customer base consists of fertility clinics, university research centers, animal breeding facilities, pharmaceutical companies, biotechnology companies, and other commercial and academic research establishments.
Neither the Toronto Venture Exchange, nor its regulation services provider (as that term is defined in the policies of the exchange), accepts responsibility for the adequacy or accuracy of this release.
For more information, please contact:
David Wolf, President & CEO Michael Bruns, CFO
Hamilton Thorne Ltd. Hamilton Thorne Ltd.
978-921-2050 978-921-2050
[email protected] [email protected]
